Dublin, Aug. 16, 2017 (GLOBE NEWSWIRE) -- The "R&D and Business Tracker for Bispecific Antibodies" newsletter has been added to Research and Markets' offering.

This information service about Bispecific Antibodies delivers 12 monthly update reports in pdf format by e-mail straight to your desk and provides online access to the author's R&D database for the subject field of the service during the one-year subscription period. Credentials to access the online database will be sent by e-mail within 24 hours after purchase.

This product consists of:

- 12 monthly update reports in pdf format delivered by e-mail
- online access to Bispecific Antibody R&D database during the 1-year subscription period

The R&D and Business Tracker for Bispecific Antibodies covers;

- T-Cell redirecting bispecific cancer antibodies
- NK cell redirecting bispecific cancer antibodies
- Bispecific immuno-oncology antibodies
- Bispecific tumor antigens targeted cancer antibodies
- Bispecific antibodies for inflammatory & autoimmune diseases
- Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases

The monthly update report about Bispecific Antibodies contains:

R&D and Technology Tracker

- Pipeline changes
- Regulatory news
- Technology validations

Business Tracker for:

- Company updates
- Collaboration
- Licensing
- Merger & acquisitions
- Financing

Clinical Trial Tracker

Scientific Publication Tracker

Featured Bispecific Antibody or Technology Profile

Featured Company Profile

Featured Target or Technology Pipeline

For more information about this newsletter visit https://www.researchandmarkets.com/research/6mq6rw/randd_and

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Immune Disorders Drugs, Oncology Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.